Abstract
Background Neonates may respond differently from adults to drug components. Hence, ingredients that seem safe in adults may not be safe in this age group. Objective To describe the content of harmful excipients in drugs used in our neonatal wards and compare the daily dose a neonate may receive with the accepted daily intake (ADI) in adults. Methods All drugs included in the hospital’s neonatal treatment guide were reviewed, using information from the package inserts or the summary of product characteristics. Those containing at least one harmful excipient (e.g., metabisulfite, sorbitol) were analyzed. Minimum and maximum usual daily drug doses were determined, and excipient exposure was estimated by extrapolation of the minimum and maximum of excipient referred to the active ingredient. These amounts were compared with ADIs for each excipient in adults. Results In total, 32 % of intravenous and 62 % of oral formulations used in neonates contained at least one harmful excipient. On quantitative analysis, 25 % of intravenous and 19 % of oral drugs contained harmful excipients exceeding the ADI in adults. Conclusion Several drugs commonly used to treat neonates contain harmful excipients in amounts that may exceed the ADI in adults. Clinicians should be aware of this to prescribe appropriate treatment in this population.
References
Shebab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. Pediatr Crit Care Med. 2009;10:256–9.
Marek E, Kraft WK. Ethanol pharmacokinetics in neonates and infants. Curr Ther Res. 2014;76:90–7.
De Cock RF, Knibbe CA, Kulo A, de Hoon J, Verbesselt R, Danhof M, et al. Developmental pharmacokinetics of propylene glycol in preterm and term neonates. Br J Clin Pharmacol. 2012;75:162–71.
Lass J, Naelapää K, Shah U, Käär R, Varendi H, Turner MA, et al. Hospitalised neonates in Estonia commonly receive potentially harmful excipients. BMC Pediatr. 2012;12:136.
Nahata MC. Safety of “inert” additives or excipients in paediatric medicines. Arch Dis Child Fetal Neonat Ed. 2009;94:392–3.
Whittaker A, Currie AE, Turner MA, Field DJ, Mulla H, Pandya HC. Toxic additives in medication for preterm infants. Arch Dis Child Fetal Neonat Ed. 2009;94:236–40.
Commission of the European Communities. Report from the Commission on Dietary Food Additive Intake in the European Union [Internet] 2001; [cited 2015 Nov]. http://ec.europa.eu/transparency/regdoc/rep/1/2001/EN/1-2001-542-EN-F1-1.Pdf.
Rowe RC, Sheskey PJ, Quinn ME. Handbook of pharmaceutical excipients. 6th ed. London: Pharmaceutical Press; 2009.
European Medicines Agency, Committee for medicinal products for human use (CHMP). Reflection paper: formulations of choice for the paediatric population [Internet]. 2006 [cited 2015 Nov]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003782.pdf.
Souza A, Santos D, Fonseca S, Medeiros M, Batista L, Turner M, et al. Toxic excipients in medications for neonates in Brazil. Eur J Pediatr. 2014;173:935–45.
Funding
None.
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Garcia-Palop, B., Movilla Polanco, E., Cañete Ramirez, C. et al. Harmful excipients in medicines for neonates in Spain. Int J Clin Pharm 38, 238–242 (2016). https://doi.org/10.1007/s11096-016-0277-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-016-0277-6